Merck EBITDA Margin 2012-2025 | MRK
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Merck (MRK) over the last 10 years. The current EBITDA margin for Merck as of December 31, 2025 is
Unlock Macrotrends Premium
Start 7-Day Free Trial
Merck EBITDA Margin Historical Data
Date
TTM Revenue
TTM EBITDA
EBITDA Margin
2025-09-30
$64.24B
$26.96B
41.97%
2025-06-30
$63.62B
$24.42B
38.39%
2025-03-31
$63.92B
$25.01B
39.13%
2024-12-31
$64.17B
$24.72B
38.52%
2024-09-30
$63.18B
$18.43B
29.17%
2024-06-30
$62.48B
$20.14B
32.24%
2024-03-31
$61.40B
$8.77B
14.29%
2023-12-31
$60.12B
$6.83B
11.35%
2023-09-30
$59.31B
$11.95B
20.15%
2023-06-30
$58.31B
$10.13B
17.38%
2023-03-31
$57.87B
$20.25B
34.99%
2022-12-31
$59.28B
$22.19B
37.43%
2022-09-30
$58.97B
$22.40B
37.98%
2022-06-30
$57.17B
$23.02B
40.26%
2022-03-31
$53.98B
$19.43B
36.00%
2021-12-31
$48.70B
$16.41B
33.70%
2021-09-30
$44.36B
$9.33B
21.04%
2021-06-30
$42.14B
$6.97B
16.53%
2021-03-31
$40.09B
$7.95B
19.84%
2020-12-31
$41.52B
$9.03B
21.76%
2020-09-30
$36.49B
$10.57B
28.96%
2020-06-30
$37.96B
$10.71B
28.22%
2020-03-31
$40.36B
$11.73B
29.07%
2019-12-31
$39.12B
$11.24B
28.72%
2019-09-30
$45.97B
$16.05B
34.90%
2019-06-30
$44.37B
$16.35B
36.84%
2019-03-31
$43.07B
$15.47B
35.92%
2018-12-31
$42.29B
$13.45B
31.80%
2018-09-30
$41.73B
$12.80B
30.68%
2018-06-30
$41.26B
$10.35B
25.07%
2018-03-31
$40.73B
$10.48B
25.74%
2017-12-31
$40.12B
$11.47B
28.60%
2017-09-30
$39.80B
$8.46B
21.26%
2017-06-30
$40.02B
$11.41B
28.51%
2017-03-31
$39.93B
$10.92B
27.35%
2016-12-31
$39.81B
$10.97B
27.56%
2016-09-30
$39.91B
$14.29B
35.80%
2016-06-30
$39.44B
$13.95B
35.37%
2016-03-31
$39.39B
$14.09B
35.78%
2015-12-31
$39.50B
$13.92B
35.25%
2015-09-30
$39.77B
$13.51B
33.97%
2015-06-30
$40.25B
$12.91B
32.08%
2015-03-31
$41.40B
$12.72B
30.73%
2014-12-31
$42.24B
$13.37B
31.66%
2014-09-30
$43.08B
$14.13B
32.79%
2014-06-30
$43.55B
$14.99B
34.41%
2014-03-31
$43.63B
$14.97B
34.31%
2013-12-31
$44.03B
$14.65B
33.28%
2013-09-30
$44.45B
$14.43B
32.46%
2013-06-30
$44.91B
$14.35B
31.96%
2013-03-31
$46.21B
$15.80B
34.19%
2012-12-31
$47.27B
$16.86B
35.66%
2012-09-30
$47.82B
$17.09B
35.73%
2012-06-30
$48.36B
$17.27B
35.72%
2012-03-31
$48.20B
$16.92B
35.11%
2011-12-31
$48.05B
$16.40B
34.14%
2011-09-30
$47.85B
$13.97B
29.20%
2011-06-30
$46.95B
$12.99B
27.67%
2011-03-31
$46.15B
$12.15B
26.32%
2010-12-31
$45.99B
$10.74B
23.35%
2010-09-30
$43.99B
$10.33B
23.48%
2010-06-30
$38.91B
$9.06B
23.28%
2010-03-31
$33.47B
$7.58B
22.65%
2009-12-31
$27.43B
$6.60B
24.06%
2009-09-30
$23.37B
$7.37B
31.54%
2009-06-30
$23.26B
$7.29B
31.35%
2009-03-31
$23.41B
$7.31B
31.23%
2008-12-31
$23.85B
$7.72B
32.35%
2008-09-30
$24.06B
$8.03B
33.35%
2008-06-30
$24.19B
$7.72B
31.92%
2008-03-31
$24.25B
$7.74B
31.90%
2007-12-31
$24.20B
$7.61B
31.43%
2007-09-30
$24.00B
$6.36B
26.50%
2007-06-30
$23.33B
$5.82B
24.94%
2007-03-31
$23.00B
$5.83B
25.37%
2006-12-31
$22.64B
$5.96B
26.31%
2006-09-30
$22.36B
$6.65B
29.74%
2006-06-30
$22.36B
$7.53B
33.68%
2006-03-31
$22.06B
$7.58B
34.37%
2005-12-31
$22.01B
$7.57B
34.38%
2005-09-30
$22.03B
$7.55B
34.28%
2005-06-30
$22.15B
$7.41B
33.44%
2005-03-31
$22.70B
$8.01B
35.26%
2004-12-31
$22.97B
$8.21B
35.73%
2004-09-30
$22.82B
$8.81B
38.60%
2004-06-30
$23.04B
$9.72B
42.18%
2004-03-31
$22.55B
$9.61B
42.64%
2003-12-31
$22.49B
$9.88B
43.95%
2003-09-30
$7.90B
$10.21B
129.23%
2003-06-30
$7.56B
$10.01B
132.33%
2003-03-31
$14.85B
$10.28B
69.23%
2002-12-31
$21.45B
$10.34B
48.23%
2002-09-30
$16.45B
$9.94B
60.42%
2002-06-30
$22.94B
$10.46B
45.61%
2002-03-31
$22.02B
$10.50B
47.68%
2001-12-31
$21.20B
$10.55B
49.77%
2001-09-30
$46.63B
$11.28B
24.20%
2001-06-30
$45.27B
$11.03B
24.37%
2001-03-31
$42.86B
$10.89B
25.42%
2000-12-31
$40.36B
$10.69B
26.47%
2000-09-30
$37.86B
$10.30B
27.20%
2000-06-30
$35.49B
$9.78B
27.56%
2000-03-31
$34.03B
$9.38B
27.57%
1999-12-31
$32.71B
$9.06B
27.68%
1999-09-30
$31.28B
$8.78B
28.06%
1999-06-30
$29.92B
$8.97B
29.99%
1999-03-31
$28.38B
$8.29B
29.20%
1998-12-31
$26.90B
$7.66B
28.46%
1998-09-30
$25.60B
$7.57B
29.55%
1998-06-30
$24.69B
$6.51B
26.36%
1998-03-31
$24.13B
$6.45B
26.72%
1997-12-31
$23.64B
$6.36B
26.90%
1997-09-30
$22.81B
$6.20B
27.18%
1997-06-30
$21.87B
$6.08B
27.81%
1997-03-31
$20.87B
$5.89B
28.22%
1996-12-31
$19.83B
$5.67B
28.60%
1996-09-30
$18.98B
$4.95B
26.08%
1996-06-30
$18.17B
$4.82B
26.52%
1996-03-31
$17.39B
$4.70B
27.00%
1995-12-31
$16.68B
$4.60B
27.55%
1995-09-30
$16.00B
$4.06B
25.39%
1995-06-30
$15.62B
$4.06B
26.00%
1995-03-31
$15.27B
$4.10B
26.82%
1994-12-31
$14.97B
$4.10B
27.39%
1994-09-30
$14.10B
$4.52B
32.09%
1994-06-30
$12.85B
$4.32B
33.61%
1994-03-31
$11.63B
$4.06B
34.90%
1993-12-31
$10.50B
$3.91B
37.27%
1993-09-30
$10.10B
$3.72B
36.81%
1993-06-30
$10.02B
$3.60B
35.97%
1993-03-31
$9.82B
$3.55B
36.14%
1992-12-31
$9.66B
$3.49B
36.14%
1992-09-30
$9.38B
$3.44B
36.73%
1992-06-30
$9.03B
$3.34B
37.00%
1992-03-31
$8.78B
$3.22B
36.71%
1991-12-31
$8.60B
$3.11B
36.14%
1991-09-30
$8.39B
$3.00B
35.79%
1991-06-30
$8.19B
$2.89B
35.26%
1991-03-31
$7.96B
$2.77B
34.78%
1990-12-31
$7.67B
$2.65B
34.57%
1990-09-30
$7.33B
$2.53B
34.45%
1990-06-30
$7.05B
$2.43B
34.49%
1990-03-31
$6.74B
$2.32B
34.39%
1989-12-31
$6.55B
$2.24B
34.14%
1989-09-30
$6.32B
$2.15B
33.96%
1989-06-30
$6.16B
$2.05B
33.22%
1989-03-31
$6.07B
$1.95B
32.17%
1988-12-31
$5.94B
$1.87B
31.43%
1988-09-30
$5.80B
$1.77B
30.48%
1988-06-30
$5.64B
$1.64B
29.16%
1988-03-31
$5.39B
$1.51B
27.94%
1987-12-31
$5.06B
$1.37B
27.05%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $299.893B
$65.011B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
